Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Antonio Bunker-Huertas

Internal Medicine Zephyrhills, FL Medical Doctor

NPI 1265546121 CMS profile 1196902

36763 Eiland Blvd Ste 102, Zephyrhills, FL 33542

Open in the dashboard

General payments

$11,146

666 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Antonio Bunker-Huertas of Zephyrhills, FL is reported in the CMS Open Payments database as having received $11,146 across 666 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $665 35
2024 General $1,908 109
2023 General $1,566 91
2022 General $2,187 125
2021 General $2,413 154
2020 General $1,438 90
2019 General $969 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Antonio Bunker-Huertas
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Antonio Bunker-Huertas were reported at $665. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Antonio Bunker-Huertas Internal Medicine median Middle half National median
2019 $969 $159 $48–$570 $163
2020 $1,438 $119 $33–$402 $114
2021 $2,413 $135 $37–$521 $132
2022 $2,187 $141 $42–$496 $149
2023 $1,566 $149 $45–$519 $160
2024 $1,908 $154 $47–$537 $164
2025 $665 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,379 110 payments
  2. GlaxoSmithKline, LLC. $834 47 payments
  3. Amgen Inc. $796 56 payments
  4. Lilly USA, LLC $760 44 payments
  5. AbbVie, Inc. $751 42 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $717 43 payments
  7. Amarin Pharma Inc. $509 37 payments
  8. Pfizer Inc. $473 31 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $433 23 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $398 15 payments
  11. Other $4,098 218 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,033 664 payments
  2. Education $114 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,099 84 payments
  2. RYBELSUS $1,025 79 payments
  3. XIFAXAN $717 43 payments
  4. TRELEGY ELLIPTA $684 37 payments
  5. Repatha $649 47 payments
  6. UBRELVY $497 26 payments
  7. Vascepa $449 34 payments
  8. MOUNJARO $437 23 payments
  9. Kerendia $398 15 payments
  10. XARELTO $396 23 payments
  11. Other $8,384 510 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 161 drugs

Part D claims

8,567

Median for Internal Medicine: 777

Drug cost

$968,402

Median for Internal Medicine: $73,373

Branded share of claims

21.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 74 $127,655
Januvia Sitagliptin Phosphate Brand 80 $113,034
Farxiga Dapagliflozin Propanediol Brand 75 $88,376
Eliquis Apixaban Brand 87 $79,601
Jardiance Empagliflozin Brand 55 $70,692
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 53 $61,632
Trulicity Dulaglutide Brand 29 $39,475
Rybelsus Semaglutide Brand 16 $35,811
Xarelto Rivaroxaban Brand 35 $35,317
Linzess Linaclotide Brand 34 $27,032

The 10 drugs with the highest cost, of 161 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$52,875

Of which drugs: $5,542

Medicare patients

230

Average age 74

Services billed

1,054

127 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 42%
Ischemic heart disease 37%
Chronic kidney disease 36%
COPD 30%
Depression 29%
Osteoporosis 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 39 41 $3,305

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $122
$122 — —
Tirosint
  • IBSA Pharma Inc. $114
$114 — —
MOUNJARO
  • Lilly USA, LLC $110
$110 13 —
JARDIANCE
  • Lilly USA, LLC $79
  • Boehringer Ingelheim Pharmaceuticals, Inc. $17
$97 55 —
NURTEC ODT
  • PFIZER INC. $95
$95 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

666 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record